Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early selective Curosurf treatment for neonatal RDS guided by lamellar body count
ISRCTN41781424Phase 4Completed
- Sponsor
- Individual sponsor
- Start
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Individual sponsor. Primary endpoint: Mechanical ventilation or death within the first 5 days of life. Started Mar 2007; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ISRCTN41781424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN41781424.